|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
WO2020085504A1
(ja)
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
MD4051678T2
(en)
|
2019-10-28 |
2026-07-31 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of the KRAS G12C mutant
|
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
US12702658B2
(en)
|
2020-04-24 |
2026-08-11 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
CA3191279A1
(en)
|
2020-08-28 |
2022-03-03 |
Yi Liu |
Heterocyclic compounds and uses thereof
|
|
WO2022109487A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
WO2022135470A1
(zh)
*
|
2020-12-22 |
2022-06-30 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
|
WO2022192790A1
(en)
*
|
2021-03-12 |
2022-09-15 |
Bristol-Myers Squibb Company |
Kras inhibitors
|
|
CN115141215B
(zh)
*
|
2021-03-30 |
2023-09-15 |
上海德琪医药科技有限公司 |
Kras g12d蛋白抑制剂和其用途
|
|
EP4329888A1
(en)
*
|
2021-04-29 |
2024-03-06 |
Amgen Inc. |
2-aminobenzothiazole compounds and methods of use thereof
|
|
WO2022232331A1
(en)
*
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
AU2022281749A1
(en)
*
|
2021-05-24 |
2023-11-30 |
280 Bio, Inc. |
Nitrogen-containing heterocyclic compound, method for preparing same and use of same
|
|
WO2023284881A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as kras g12d inhibitors
|
|
JP2024532735A
(ja)
*
|
2021-08-10 |
2024-09-10 |
アムジエン・インコーポレーテツド |
複素環式化合物及び使用方法
|
|
WO2023020519A1
(en)
*
|
2021-08-18 |
2023-02-23 |
Jacobio Pharmaceuticals Co., Ltd. |
1, 4-oxazepane derivatives and uses thereof
|
|
WO2023039240A1
(en)
*
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
|
WO2023061294A1
(zh)
*
|
2021-10-13 |
2023-04-20 |
再鼎医药(上海)有限公司 |
含氮杂环类衍生物调节剂、其制备方法及应用
|
|
WO2023072188A1
(zh)
*
|
2021-10-29 |
2023-05-04 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
US20260200925A1
(en)
*
|
2021-11-24 |
2026-07-16 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras mutated proteins
|
|
EP4405337A4
(en)
*
|
2021-11-30 |
2025-11-26 |
Beta Pharma Inc |
Fused pyrimidine derivatives as kras oncoprotein inhibitors
|
|
WO2023114733A1
(en)
*
|
2021-12-13 |
2023-06-22 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
WO2023137223A1
(en)
*
|
2022-01-17 |
2023-07-20 |
Newave Pharmaceutical Inc. |
Pan-kras inhibitors and uses thereof
|
|
WO2023138583A1
(zh)
*
|
2022-01-21 |
2023-07-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
IL314486A
(en)
*
|
2022-02-03 |
2024-09-01 |
Mirati Therapeutics Inc |
Quinazoline compounds inhibit PAN-KRAS
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
JP2025508702A
(ja)
*
|
2022-02-16 |
2025-04-10 |
アムジエン・インコーポレーテツド |
キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
WO2023172737A1
(en)
|
2022-03-11 |
2023-09-14 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
JP2025510656A
(ja)
*
|
2022-03-24 |
2025-04-15 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
複素環式化合物、その組成物、及びそれらを用いた治療方法
|
|
US20240109918A1
(en)
*
|
2022-05-04 |
2024-04-04 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN117327102B
(zh)
*
|
2022-06-30 |
2026-04-28 |
重庆华森英诺生物科技有限公司 |
Kras抑制剂、其制备方法及应用
|
|
WO2024008068A1
(en)
*
|
2022-07-04 |
2024-01-11 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
WO2024008179A1
(en)
*
|
2022-07-07 |
2024-01-11 |
Beigene, Ltd. |
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
|
|
AU2023320565A1
(en)
|
2022-08-05 |
2025-01-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
TW202426451A
(zh)
*
|
2022-08-24 |
2024-07-01 |
大陸商泰勵生物科技(上海)有限公司 |
具有抗kras突變腫瘤活性的化合物
|
|
EP4577214A2
(en)
*
|
2022-08-26 |
2025-07-02 |
Merck Sharp & Dohme LLC |
Small molecule inhibitors of kras proteins
|
|
WO2024045066A1
(en)
*
|
2022-08-31 |
2024-03-07 |
Nikang Therapeutics, Inc. |
Alkylidene carbamate as kras inhibitors
|
|
WO2024054926A1
(en)
*
|
2022-09-07 |
2024-03-14 |
Bristol-Myers Squibb Company |
Kras g12d inhibitors
|
|
WO2024054625A2
(en)
*
|
2022-09-08 |
2024-03-14 |
Nikang Therapeutics, Inc. |
Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway
|
|
WO2024056063A1
(zh)
*
|
2022-09-16 |
2024-03-21 |
南京明德新药研发有限公司 |
含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物
|
|
WO2024061365A1
(zh)
*
|
2022-09-22 |
2024-03-28 |
成都奥睿药业有限公司 |
嘧啶并环类化合物及其制备方法与用途
|
|
WO2024063576A1
(ko)
*
|
2022-09-23 |
2024-03-28 |
일동제약(주) |
Kras 저해 물질로서 신규한 퀴나졸린 화합물
|
|
CN117917416A
(zh)
|
2022-10-21 |
2024-04-23 |
上海领泰生物医药科技有限公司 |
Kras g12d降解剂及其制备方法和应用
|
|
EP4631942A1
(en)
|
2022-10-21 |
2025-10-15 |
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. |
Pan-kras degrading agent, and preparation method therefor and use thereof
|
|
KR20250109197A
(ko)
|
2022-11-21 |
2025-07-16 |
트리라인 바이오사이언시스, 인크. |
스피로환식 디하이드로피라노피리미딘 KRas 억제제
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
EP4680609A1
(en)
|
2023-03-15 |
2026-01-21 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
CN121487738A
(zh)
|
2023-03-30 |
2026-02-06 |
锐新医药公司 |
诱导ras gtp水解的组合物和其用途
|
|
CN118772151A
(zh)
*
|
2023-04-04 |
2024-10-15 |
泰励生物科技(上海)有限公司 |
具有抗kras突变肿瘤活性的化合物
|
|
CN121487951A
(zh)
|
2023-04-07 |
2026-02-06 |
锐新医药公司 |
大环ras抑制剂
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
AU2024251341A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
EP4695261A1
(en)
|
2023-04-14 |
2026-02-18 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
WO2024238633A2
(en)
*
|
2023-05-15 |
2024-11-21 |
Mirati Therapeutics, Inc. |
Kras g12s and g12c inhibitors
|
|
WO2025006967A1
(en)
|
2023-06-30 |
2025-01-02 |
Bristol-Myers Squibb Company |
Kras inhibitors
|
|
EP4735451A1
(en)
|
2023-06-30 |
2026-05-06 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
WO2025019823A1
(en)
*
|
2023-07-20 |
2025-01-23 |
Merck Sharp & Dohme Llc |
Small molecule protein degraders of kras g12d mutant
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
KR20260054710A
(ko)
|
2023-08-17 |
2026-04-22 |
트리라인 바이오사이언시스, 인크. |
스피로시클릭 디히드로피라노피리미딘 KRas 저해제
|
|
AU2024337016A1
(en)
*
|
2023-09-08 |
2026-04-16 |
Tyligand Bioscience (Shanghai) Limited |
Ras inhibitor
|
|
WO2025064848A1
(en)
|
2023-09-21 |
2025-03-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyridine kras inhibitors
|
|
KR20260084633A
(ko)
|
2023-10-10 |
2026-06-05 |
청두 하이퍼웨이 파마슈티컬스 컴퍼니 리미티드 |
축합 고리 화합물 및 kras 억제제로서의 응용
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
KR20260096846A
(ko)
|
2023-10-20 |
2026-06-24 |
머크 샤프 앤드 돔 엘엘씨 |
Kras 단백질의 소분자 억제제
|
|
TW202545934A
(zh)
*
|
2024-02-05 |
2025-12-01 |
日商安斯泰來製藥股份有限公司 |
包含具有突變kras蛋白分解誘導作用之雜環化合物的抗體藥物複合體
|
|
AU2025218254A1
(en)
*
|
2024-02-06 |
2026-07-23 |
Windermere Therapeutics, Inc. |
Kras(g12d) inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025218811A1
(zh)
*
|
2024-04-19 |
2025-10-23 |
领泰生物医药(绍兴)有限公司 |
pan-KRAS靶向蛋白降解剂及其制备方法和应用
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|